Protalix BioTherapeutics, Inc. (PLX)
| Market Cap | 204.65M +60.4% |
| Revenue (ttm) | 80.62M +30.1% |
| Net Income | 18.95M +201.9% |
| EPS | 0.24 +205.3% |
| Shares Out | 80.57M |
| PE Ratio | 10.74 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 490,228 |
| Open | 2.610 |
| Previous Close | 2.610 |
| Day's Range | 2.530 - 2.620 |
| 52-Week Range | 1.520 - 3.190 |
| Beta | 0.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell... [Read more]
Financial Performance
Financial StatementsNews
Protalix BioTherapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth driven by Elfabrio sales and a $25M milestone, with net income rising to $3.8M. The company maintains a robust cash position, is on track for full-year guidance, and expects continued pipeline progress, especially for PRX-115.
Protalix BioTherapeutics Earnings release: Q2 2026
Protalix BioTherapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Protalix BioTherapeutics Quarterly report: Q2 2026
Protalix BioTherapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Protalix BioTherapeutics Slides: Corporate presentation
Protalix BioTherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025...
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on t...
Protalix BioTherapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw a $25M milestone from Chiesi, driving net income to $18.2M and cash to $51M. Revenue guidance for 2026 is reaffirmed at $78–$83M, with strong momentum for Elfabrio and ongoing PRX-115 clinical progress.
Protalix BioTherapeutics Earnings release: Q1 2026
Protalix BioTherapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Protalix BioTherapeutics Quarterly report: Q1 2026
Protalix BioTherapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Protalix BioTherapeutics Slides: Corporate presentation
Protalix BioTherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25...
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on th...
Protalix BioTherapeutics Proxy statement: Proxy filing
Protalix BioTherapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Protalix BioTherapeutics Earnings Call Transcript: Q4 2025
EU approval of Elfabrio's four-week dosing triggered a $25M milestone, boosting projected 2026 cash to $50M and supporting revenue growth over 50%. Pipeline advances in gout and renal indications, with strong commercial execution and high-margin contributions from Chiesi.
Protalix BioTherapeutics Annual report: Q4 2025
Protalix BioTherapeutics has published its Q4 2025 annual report on March 18, 2026.
Protalix BioTherapeutics Earnings release: Q4 2025
Protalix BioTherapeutics released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in adults living with Fabry disease...
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, March 11, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on...
Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio
Chiesi Global Rare Diseases and Protalix (PLX) BioTherapeutics announced that the European Commission has approved the 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults living with Fabry dise...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the FDA-approve...
Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing
Chiesi Global Rare Diseases and Protalix (PLX) BioTherapeutics announced an update on Elfabrio. The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positiv...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2...
Protalix BioTherapeutics Letter to Stockholders
CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization o...
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications Protalix i...